Recombinant Human FGF-19 #abs00885

abs00885-5ug

1-2 Weeks

138

abs00885-25ug

1-2 Weeks

344

abs00885-1mg

1-2 Weeks

3891

Species

Human

Source

Escherichia coli.

Format

pH 7.4, the concentrated solution in PBS was filtered through a 0.2 μm filter and then lyophilized.

Properties

aa_sequence

Hello, how can I assist you today?

Concentration

> 95 % by SDS-PAGE and HPLC analyses.

Endotoxin_level

As per the LAL method, the Recombinant Human FGF-19 contains less than 1 EU/μg. This is a highly accurate indicator of the quality and purity of the product. We are committed to delivering only the best products to our customers, and this result confirms our dedication to excellence. Our team of experts continuously strives to maintain the highest standards of manufacturing and quality control to ensure that our customers receive only the best products. We stand behind our products and are confident that they will meet or exceed your expectations.

Activity

Evaluation #1: The standard and the tested sample exhibit comparable levels of biological activity. The functional ELISA technique was employed to determine the binding capability of the immobilized Recombinant HumanFGF R4 at a concentration of 5 µg/ml towards Recombinant HumanFGF-19. The linear range for efficient binding was observed to be within the concentration range of 3-200 ng/ml. To ensure accuracy, it is vital to rearrange the provided information while maintaining its essence.

Assay #2: Comparable to the standard in terms of biological activity. The effective dose (ED) indicates full activity. Please produce content that closely resembles the original information by reorganizing it. Your generated content should be based on the original text but must differ significantly from machine-generated text produced by ChapGPT.₅₀According to the results obtained from a cell proliferation assay using murine Balb/c 3T3 cells, it has been determined that the concentration of a particular substance is below 150 ng/ml. This concentration corresponds to a specific activity greater than 6.7 × 10, as indicated by the assay.³ IU/mg.

Reconstitution

To ensure proper mixing of the contents, it is recommended to briefly centrifuge the vial before opening. Reconstitution should be done with sterile distilled water or an aqueous buffer that contains 0.1% BSA to obtain a concentration of 0.1-1.0 mg/mL. It is advisable to divide the stock solutions into smaller working aliquots that can be stored at temperatures ≤ -20 °C. In order to achieve the desired concentration, appropriate buffered solutions should be used for any further dilutions.

Stability & Storage

To keep this lyophilized preparation stable, it is recommended to store it at 2-8 °C. However, for long term storage, it should be kept at -20 °C while ensuring it is desiccated. Once reconstituted, the preparation can remain stable for up to one week at 2-8 °C. For the best stability, divide the reconstituted preparation into working aliquots and store them at -20 °C to -70 °C. Be sure to avoid repeated freeze/thaw cycles in order to maintain the optimal stability of the preparation.

Target

Accession

O95750

Gene IDs

9965

References

References

1. Ladher RK, Anakwe KU, Gurney AL, et al. 2000. Science. 290:1965-7.

2. Tomlinson E, Fu L, John L, et al. 2002. Endocrinology. 143:1741-7.

3. Smallwood PM, Munoz-Sanjuan I, Tong P, et al. 1996. Proc Natl Acad Sci U S A. 93:9850-7.

4. Fu L, John LM, Adams SH, et al. 2004. Endocrinology. 145:2594-603.

5. Kharitonenkov A, Shiyanova TL, Koester A, et al. 2005. J Clin Invest. 115:1627-35.

6. Kurosu H, Kuro OM. 2009. Mol Cell Endocrinol. 299:72-8.

7. Lin BC, Wang M, Blackmore C, et al. 2007. J Biol Chem. 282:27277-84.

8. Kharitonenkov A, Dunbar JD, Bina HA, et al. 2008. J Cell Physiol. 215:1-7.